RECRUITING

Mood Effects of Serotonin Agonists: Depression

Conditions

LSD Major Depressive Disorder Depression

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.

Official Title

Mood Effects of Serotonin Agonists: Depression

Quick Facts

Study Start:2025-06-09

Study Completion:2026-06-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07017478

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 40 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* English Fluency * high school education or higher * BMI between 19-30 kg/m2	* individuals with a medical condition contraindicating study participation as determined by the study physician (e.g., liver disease, abnormal EKG, liver or cardiovascular disease) * high blood pressure (\>140/90) * current suicidal ideation or suicide attempt in past 12 months * past year severe substance use disorder * personal or first-degree relative with history of psychosis * currently taking any psychiatric medication (for conventional antidepressants must be off for ≥ 2 weeks) * active panic disorder * severe obsessive-compulsive disorder * severe post-traumatic stress disorder * women who are pregnant or planning to become pregnant

Inclusion Criteria

Exclusion Criteria

* English Fluency
* high school education or higher
* BMI between 19-30 kg/m2

* individuals with a medical condition contraindicating study participation as determined by the study physician (e.g., liver disease, abnormal EKG, liver or cardiovascular disease)
* high blood pressure (\>140/90)
* current suicidal ideation or suicide attempt in past 12 months
* past year severe substance use disorder
* personal or first-degree relative with history of psychosis
* currently taking any psychiatric medication (for conventional antidepressants must be off for ≥ 2 weeks)
* active panic disorder
* severe obsessive-compulsive disorder
* severe post-traumatic stress disorder
* women who are pregnant or planning to become pregnant

Contacts and Locations

Study Contact

Hanna Molla

CONTACT

7737023560

hmolla@uchicago.edu

Principal Investigator

Hanna Molla

PRINCIPAL_INVESTIGATOR

University of Chicago

Study Locations (Sites)

University of Chicago

Chicago, Illinois, 60637

United States

Collaborators and Investigators

Sponsor: University of Chicago

Hanna Molla, PRINCIPAL_INVESTIGATOR, University of Chicago

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-09

Study Completion Date2026-06-01

Study Record Updates

Study Start Date2025-06-09

Study Completion Date2026-06-01

Terms related to this study

Additional Relevant MeSH Terms

LSD
Major Depressive Disorder
Depression